Clicky

Forte Biosciences, Inc.(FBRX)

Description: Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients.


Keywords: Medicine Immunology Monoclonal Antibodies Dermatology Atopic Dermatitis Dermatitis Skin Diseases Type I Hypersensitivity Atopy Inflammatory Skin Diseases Sodium Hypochlorite Washes Treatment Of Inflammatory Skin Diseases

Home Page: www.fortebiorx.com

FBRX Technical Analysis

3060 Pegasus Park Drive
Dallas, TX 75247
United States
Phone: 310 618 6994


Officers

Name Title
Dr. Paul A. Wagner Ph.D. CEO & Chairman
Mr. Antony A. Riley CPA Chief Financial Officer
Dr. Hubert C. Chen M.D. Pres & Chief Scientific Officer
Mr. Christopher Roenfeldt Chief Operating Officer
Mr. Steven Ruhl Chief Technical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4854
Price-to-Sales TTM: 0
IPO Date: 2017-04-13
Fiscal Year End: December
Full Time Employees: 6
Back to stocks